Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

National Institute of Allergy and Infectious Diseases (NIAID)99 enrolled

Overview

Palifermin is a modified version of a naturally occurring human growth factor that is currently approved by the FDA to treat blood cancers. The purpose of this study is to determine whether palifermin can increase CD4 counts in treatment-experienced HIV infected adults.

Antiretroviral therapy (ART) has dramatically improved the clinical outcome for HIV infected adults; however, some people on potent ART experience poor recovery of CD4 counts despite maximum suppression of viral load. Such uncontrolled HIV infection is associated with the reduced ability by the human body to create new T cells (or thymopoiesis). HIV infected adults experiencing reduced thymopoiesis are at increased risk of clinical disease progression. The thymus is the primary site for CD4 cell development; research suggests that keratinocyte growth factor (KGF) may enhance thymus activity in individuals who exhibit reduced thymopoiesis. Palifermin is a modified version of the naturally occurring KGF that is approved to treat people with hematologic malignancies. The purpose of this study is to evaluate the safety and efficacy of palifermin in increasing CD4 counts, through enhanced thymopoiesis, in treatment-experienced HIV infected adults with suppressed viral loads but low CD4 counts. This study will last 24 weeks. Participants will be randomly assigned to one of four arms: * Arm A participants will receive placebo * Arm B participants will receive palifermin 20 mcg/kg * Arm C participants will receive palifermin 40 mcg/kg * Arm D participants will receive palifermin 60 mcg/kg Participants will receive intravenous doses of their assigned intervention on Days 1, 2, and 3. All participants must remain on their current ART regimen for the duration of the study. ART will not be provided by the study. There will be six study visits, and they will occur at Weeks 1, 2, 4, 8, 12, and 24. All visits will include a targeted physical exam and blood and urine collection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

HIV Infections

Interventions

PaliferminDRUG

Keratinocyte growth factor administered via injection

Palifermin placeboDRUG

Keratinocyte growth factor placebo administered via injection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV infected * Receiving potent ART, defined as a combination of three or more antiretroviral drugs for at least 6 months prior to study entry * CD4 count of 200 cells/mm3 or less within 30 days prior to study entry * Documented CD4 count obtained at study screening * Documented current, persistent viral load less than or equal to 200 copies/ml for at least 6 months prior to study entry * Willing to use acceptable forms of contraception for the duration of the study Exclusion Criteria: * Active pancreatitis * Androgens, Immunomodulators (e.g., growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons), or investigational ART within 30 days prior to study entry * Systemic cancer chemotherapy within 30 days prior to study entry, or history of radiation therapy to the neck and chest regions at any time. * Allergy or sensitivity to any component of palifermin * Prior treatment with palifermin or other keratinocyte growth factors * Current drug or alcohol use that, in the opinion of the investigator, may interfere with study participation * Serious illness or recent surgery that requires systemic treatment or hospitalization. Participants who have completed therapy or are clinically stable on therapy for at least 30 days prior to study entry are not excluded. * Active cancer * HIV-1 RNA levels \>200 copies/mL within 6 months prior to study entry * Pregnant or breastfeeding

Locations (22)

USC CRS

Los Angeles, California, United States

Outcomes

Primary Outcomes

Change in Absolute CD4+ Lymphocyte Counts From Baseline (Average of Pre-entry and Entry Values)

Median and inter-quartile range of the change in absolute CD4 count from baseline to study week 12 were calculated for each treatment arm. Baseline CD4+ count was defined as the average of pre-entry and entry CD4 count. If one evaluation was missing, the other one was used. If a subject missed a week 12 CD4 count evaluation, then the CD4 count evaluation obtained after starting study treatment and closest in time to week 12 (using the earlier evaluation if necessary to break a tie) was used in place of the missing week 12 evaluation.

Time frame: Pre-entry, entry, study week 12

Secondary Outcomes

Qualitative Hepatitis C Virus RNA

Time frame: At study entry

Grade 3 or 4 Toxicity for Signs and Symptoms From Randomization to Week 24

Number of subjects had a grade 3 or 4 toxicity for signs and symptoms. The toxicity grade scale has the following meaning: 1=mild, 2=moderate, 3=severe, 4=life-threatening.

Time frame: From randomization to week 24

Change in Naive CD4+ Cell Counts From Randomization

Time frame: randomization, day 2, study weeks 1, 2, 4, 8, 12 and 24

Change in CT Thymic Index From Randomization

CT thymic index was evaluated at randomization and study week 12, ranging from 0 to 5 whereby 0 means lack of thymic tissue and an organ entirely replaced by fat, 1 means barely recognizable thymic tissue, 2 means minimal soft tissue, 3 means obvious thymic tissue, 4 means moderate thymic tissue, 5 means thymic mass of possible concern for thymoma. Change in CT thymic index from randomization to study week 12 was calculated for participants with both evaluations. The number of participants in each change group was reported by treatment arm.

Time frame: randomization, study week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.